Dermal fibroblasts display similar phenotypic and differentiation capacity to fat-derived mesenchymal stem cells, but differ in anti-inflammatory and angiogenic potential

Abstract

Background

Mesenchymal stem cells (MSCs) are multipotent stem cells able to differentiate into different cell lineages. However, MSCs represent a subpopulation of a more complex cell composition of stroma cells contained in mesenchymal tissue. Due to a lack of specific markers, it is difficult to distinguish MSCs from other more mature stromal cells such as fibroblasts, which, conversely, are abundant in mesenchymal tissue. In order to find more distinguishing features between MSCs and fibroblasts, we studied the phenotypic and functional features of human adipose-derived MSCs (AD-MSCs) side by side with normal human dermal fibroblasts (HNDFs) in vitro.

Methods

AD-MSCs and HNDFs were cultured, expanded and phenotypically characterized by flow cytometry (FC). Immunofluorescence was used to investigate cell differentiation. ELISA assay was used to quantify angiogenic factors and chemokines release. Cultures of endothelial cells (ECs) and a monocyte cell line, U937, were used to test angiogenic and anti-inflammatory properties.

Results

Cultured AD-MSCs and HNDFs display similar morphological appearance, growth rate, and phenotypic profile. They both expressed typical mesenchymal markers—CD90, CD29, CD44, CD105 and to a minor extent, the adhesion molecules CD54, CD56, CD106 and CD166. They were negative for the stem cell markers CD34, CD146, CD133, CD117. Only aldehyde dehydrogenase (ALDH) was expressed. Neither AD-MSCs nor HNDFs differed in their multi-lineage differentiation capacity; they both differentiated into osteoblast, adipocyte, and also into cardiomyocyte-like cells. In contrast, AD-MSCs, but not HNDFs, displayed strong angiogenic and anti-inflammatory activity. AD-MSCs released significant amounts of VEGF, HGF and Angiopoietins and their conditioned medium (CM) stimulated ECs proliferation and tube formations. In addition, CM-derived AD-MSCs (AD-MSCs-CM) inhibited adhesion molecules expression on U937 and release of RANTES and MCP-1. Finally, after priming with TNFα, AD-MSCs enhanced their anti-inflammatory potential; while HNDFs acquired pro-inflammatory activity.

Conclusions

AD-MSCs cannot be distinguished from HNDFs in vitro by evaluating their phenotypic profile or differentiation potential, but only through the analysis of their anti-inflammatory and angiogenic properties. These results underline the importance of evaluating the angiogenic and anti-inflammatory features of MSCs preparation. Their priming with inflammatory cytokines prior to transplantation may improve their efficacy in cell-based therapies for tissue regeneration.

Background

Within the panorama of adult stem cells, mesenchymal stem cells (MSCs) have been proposed for application in cell-based therapies because of their multipotential differentiation capacity, easy tissue accessibility and capacity for ex-
MSCs are localized in the stroma of tissue or organs, and they have been isolated and characterized from different adult tissue sources such as bone marrow (BM), skeletal muscle, pancreas, vessels, dental pulp and adipose tissue [2–7]. Different methods for their isolation and culture expansion have been described [3, 4, 8]. The majority of techniques used direct adhesion to tissue culture plastic to separate MSCs from the unwanted cells contained in the stroma [5, 8]. This procedure can be easily applied to separate MSCs from BM or umbilical cord blood. In fact, unwanted cells continue to float in the culture medium and can be easily discarded by replacing the culture medium. The technique to separate MSCs from not-hematopoietic tissue, for example adipose tissue, is more complex because MSCs are only a small cell subpopulation of the total stromal cells that adhere to plastic after seeding. In particular, fibroblasts are adherent proliferating cells which are difficult to remove because they can survive and grow even under extremely selective culture conditions.

Fibroblasts are considered mature mesenchymal cells that are particularly abundant in the connective of each organ and tissue. Therefore, these cells are the most frequent contaminating cell phenotype present in many cell culture systems [9]. Not only is it difficult to apply techniques which successfully eliminate fibroblasts from a culture, it is also particularly complex to distinguish MSCs from fibroblasts in the same culture. Fibroblasts and MSCs have an extremely similar morphological appearance [10]; they both proliferate well and have many identical cell surface markers [10]. MSCs lack a specific surface antigen that precisely differentiates these cells from fibroblasts. Stro-1, and more recently CD146, have been claimed as specific markers for MSCs [11, 12, 13]. However, these markers seem limited to MSCs derived from BM (BM-MSCs) or from renal tissue, since adipose-derived MSCs (AD-MSCs), for example, did not display these markers [14, 15]. In spite of these differences, MSCs of different tissue origin possess a very similar phenotypic profile. They usually express high levels of mesenchymal markers and in general do not express hematopoietic markers [14, 15]. Until now, the best way to distinguish MSCs from fibroblasts is based on the analysis of the functional properties of these two kinds of cells; MSCs self-renew and retain multipotent differentiation capacity, while fibroblasts seem more limited in both these functional properties [14]. However, a deeper comparative analysis between MSCs and fibroblasts is lacking. In particular, given the importance of the application of AD-MSCs in cell based therapies, it is relevant to distinguish them from fibroblasts which significantly contribute to the stromal cell population of adipose tissue. In order to fill this gap and to find functional features that may better help to distinguish culture of AD-MSCs from fibroblasts, in the present work we investigated the phenotypic and functional properties of three different preparations of human AD-MSCs and two normal human dermal fibroblast (HNDFs) cell lines side by side. We confirm that HNDFs and AD-MSCs display similar phenotypic and functional features, including the capacity to differentiate into different cell lineages. We here demonstrate for the first time that, while AD-MSCs possess a strong anti-inflammatory and angiogenic potential, HNDFs do not.

Methods

Isolation and culture of human AD-MSCs and Fibroblasts

Human fat specimens were excised from 3 patients after approval by the ethics committee of "MIULLI" General Regional Hospital (Acquaviva, Bari). Informed consent was obtained from each human donor. Adipose tissue samples were collected under sterile conditions from 3 male donors (aged from 40 and 60 years) who underwent standard laparoscopic surgery (uncomplicated colecistectomy and inguinal hernia), after a negative blood screening for HIV, HBV, HCV, Treponema pallidum, HTLV-I and II. Each adipose tissue sample was treated and cultured separately.

Human AD-MSCs were isolated as described [3, 15]. Briefly, sterile adipose tissue samples were transferred in 50 ml falcon tubes containing PBS plus penicillin-streptomycin solution and quickly transferred at 4°C temperature to our laboratories. Each sample was repeatedly washed with PBS for blood residual and connective tissue removal. Subsequently, fat specimens were minced with scissors and washed with PBS by centrifugation at 250 × g. After liquid phase removal, collagenase solution (0,25% w/v) (SIGMA St. Louis, Mo, USA) plus 200 μl DNAase (SIGMA) at 1:10 dilution were added to pellets. All tubes were then incubated at 37°C for 2 hours. After enzymatic digestion, cells were washed by centrifugation at 250 × g for 10'. The pellets were resuspended in DMEM +10% FBS medium, filtered (100 μm) to remove undigested tissue, seeded into T 25 culture flasks and incubated at 37°C in a humidified atmosphere containing 5% CO2. The following day, the medium was aspirated and the adherent AD-MSCs were cultured in EGM medium supplemented with 10% FCS, 50 ng/ml bFGF and antibiotics (Lonza, Verviers, Belgium). The two normal human adult dermal fibroblasts (HNDFs) cell lines were purchased from Lonza (Verviers, Belgium catalogue N° CC25) and cultured under identical conditions used for AD-MSCs. Cultures were routinely passed at 70-80% of confluence and, for this study, cultures were not expanded for more than 8-10 in vitro passages. The growth rate of each AD-MSCs preparation and for HNDFs was determined as previously described [15]. Briefly, AD-MSCs and HNDFs (at passage 4) were harvested from the culture flask by treatment with trypsin (Sigma) in PBS (0.05% w/v). Following enzyme inactivation and centrifugation, cells were resuspended in EGM +10% FCS and 50 ng/ml bFGF and seeded at a final density of 2 × 10^4 cells/ml in T25 culture flasks. After a 7-day incubation, AD-MSCs and HNDFs were detached and counted by hemocytometer.

Characterization of humanAD-MSCs and HNDFs

Cultures of AD-MSCs and HNDFs were characterized by flow cytometry (FC). After trypsinization, cells were resuspended with FC buffer (pH 7.2 PBS, BSA 0.5%, Sodium Azide 0.02%) and fixed with paraformaldehyde 2%.
Growth Factor (VEGF), phycoerythrin (PE) or phycoerythrin-cyanin PC5 conjugate-antibodies were used. The expression of the following markers were investigated: CD44F, CD90PE, CD34PE, CD45F, CD54F, CD146PE, CD117PC5, CD31F, vWF-F, CD105PE, CD106PE, CD166F, CD40F, CD80F, CD86PE, FAS (CD95 member of the family of TNFα receptors), FAS-L (CD178 ligand of FAS) (Immunotech®, Milan, Italy), CD56PE (Sero-tec®, Italy), HLAIF, HLAIIPE, CD29PE, CD49dPE (Biolegend®, Italy), Stro-1PE (R&D® , Milan, Italy), CD133 (Miltenyi Biotec®, Bologna, Italy). AD-MSCs and HNDFs were incubated for 20'/room temperature in a dark room. Then cultures were collected after 72 hours at 70-80% of cell confluence and between 5-8 in vitro passages. Afterwards, AD-MSCs and HNDFs were detached with trypsin, counted and stained with Trypan Blue to detect cell viability and sealed. Fluorescence analysis was established with fluorescence inverted microscope Leica DM IL (Leica Microsystems GmbH, Wetzlar, Germany). The images were adjusted in contrast and brightness with the image processing module "Ambient LAS" for the acquisition and overlay of fluorescent images (Leica Microsystems GmbH, Wetzlar, Germany).

Evaluation of Angiogenic potential of AD-MSCs and HNDFs

ELISA-tests were performed to detect growth factors and cytokines released by AD-MSCs and HNDFs in the culture medium. Aliquots (2 ml) of conditioned medium (CM) from AD-MSCs (AD-MSCs-CM) and HNDFs (HNDFs-CM) cultures were collected after 72 hours at 70-80% of cell confluence and between 5-8 in vitro passages. Afterwards, AD-MSCs and HNDFs were detached with trypsin, counted and stained with Trypan Blue to detect cell viability and to normalize the amount of released factors in respect to the number of cells. The specific protein concentration in CMs was detected in accordance with the standard guideline protocol supplied with ELISA kit. The background value of each growth factor analyzed and contained in the control medium was subtracted. Absorbance was measured at 450 nm with a microplates photometric reader DV990BV4 (GDV, Italy). Data were expressed as mean ± SD of the secreted factor per 10^6 cells. Assay was repeated twice and each sample was run in triplicate.

Evaluation of Growth factors and cytokines production by AD-MSCs and HNDFs

To examine the capacity of AD-MSCs and HNDFs to differentiate toward adipogenic, osteogenic and cardiomyogenic cell lineages, lineage-specific induction factors were used. For osteogenic differentiation, AD-MSCs and HNDFs were cultured in the presence of DMEM/F-12 supplemented with 10% FBS, 0.1 mM dexamethasone (Sigma), 10 mM β-glycerolphosphate (Sigma) and 50 mM ascorbic acid (Sigma) for around 2 weeks. At the end of incubation, osteogenic differentiation was assessed by alkaline phosphatase (AP) expression (Milltenyi Biotec®). Fully differentiated osteoblast-like cells generated from AD-MSCs and HNDFs changed their original fibroblastic shape into a cubical/epithelial shape with prominent cytoplasmic extensions similar to an osteblast morphology. Cells stained for AP activity with NBT substrate appeared purple in color. Adipogenic differentiation was obtained upon cultivation of AD-MSCs and HNDFs in DMEM supplemented with 10% FBS, 1 mM dexamethasone (Sigma), 0.5 mM methyl-isobutylxanthine (Sigma), 10 mg/ml insulin (Invitrogen, Carlsbad, CA) and 100 mM indomethacin (Sigma) for 3 weeks. At the end of incubation, adipogenic-like cells were revealed by staining with Oil Red O (Sigma). Moreover, to confirm adipogenic differentiation, we analyzed the production of Adiponectin by HNDFs and AD-MSCs by FC using anti-Adiponectin antibodies (Sigma). Cardiomyogenic differentiation of AD-MSCs and HNDFs was assessed by immunofluorescent assay by testing the expression of anti-Desmin (Sigma), anti-Troponin C-cardiac (TNP-C), anti-Myocardial actin (MyoA), anti-Connexin 43 (Cx43) and anti-Atrial Natriuretic factor, all purchased from Biodesign International (Saco, ME, USA). Cardiomyogenic markers expression on AD-MSCs and HNDFs was analyzed upon 3 weeks of culture in EGM complete medium in the presence or in the absence of 1 μ/ml 5-azacytidine (Sigma) as previously described [15]. Briefly, after washing, the cells were incubated with secondary antibodies Beckman Coulter FITC-conjugated Goat anti Mouse-IgG (Immunotech®, Milan, Italy) for 2 hours at room temperature. Then the cells were washed to remove excess antibodies. In order to stain the nuclei, samples were incubated with DAPI (dilution 1:10,000 in PBS, Sigma) for 8' at room temperature. As negative controls, irrelevant isotype-matched antibodies were used. The slides were then mounted in Gel Mount (Biomedia, Foster City, CA) and sealed. Fluorescence analysis was established with fluorescence inverted microscope Leica DM IL (Leica Microsystems GmbH, Wetzlar, Germany). The images were adjusted in contrast and brightness with the image processing module "Ambient LAS" for the acquisition and overlay of fluorescent images (Leica Microsystems GmbH, Wetzlar, Germany).
To assess the angiogenic potential of AD-MSCs and HNDFs, we investigated the capacity of their CMs on the proliferation of Human Umbilical Vein ECs (HUVECs) (Lonza) and Human derma-derived microvascular ECs (HMECs) isolated as previously described [17]. Both ECs phenotypes were routinely maintained in EGM bullet kit (Lonza) plus 10% FCS. ECs proliferation assay was performed as described [17]. Briefly, HUVECs and HMECs (at passage 3) were harvested from culture flasks by trypsin. After enzyme inactivation and centrifugation, cells were resuspended in EGM medium ±0.2% BSA and counted. To evaluate the growth response to AD-MSCs-CM and HNDFs-CM, 0.5 ml of HUVECs and HMECs (10^6 cells) were seeded into each well of a 24-multiwell plate coated with collagen type I; after cell adhesion, medium was aspirated and replaced with EGM complete medium (+10% FCS + 50 ng/ml bFGF) supplemented or not with different dilutions of CM. Positive control growth medium consisted in EGM complete medium plus 10 ng/ml of VEGFα (Lonza). After 72 h, the wells were washed and the cells were fixed and stained. The cells were counted with a calibrated ocular eyepiece in 10 different fields at 400× magnification. Every test was run in triplicate, and at least 3 different CM preparations were tested for both AD-MSCs and HNDFs.

To test the effect of AD-MSCs-CM and HNDFs-CM on ECs tube formation, we used growth factor reduced-matrigel assay (Sigma) as described by Kleinman et al [18]. Briefly, around 50 ul of matrigel were seeded into cold (maintained at 4°C) wells of a 96-multiwell plate. After matrigel jellification at 37°C for 30', HUVECs and HMECs were seeded on matrigel at concentration of 10^4 cells/well in 50 ul of EGM control medium. After 72 h, the wells were washed and the cells were fixed and stained. The cells were counted at 10× magnification by inverted microscopy and reported as n° of tube structures/well

Evaluation of anti-inflammatory activity of AD-MSCs and NHDFs

The anti-inflammatory activity of AD-MSCs and HNDFs was tested by applying AD-MSCs-CM and HNDFs-CM on the U937 monocyte cell line (ATCC Manassas VA, USA), both in the absence and the presence of inflammatory stimuli LPS 1 μg/ml (Sigma) and TNFα 25 ng/ml (Sigma). The expression of the adhesion molecules CD54, CD44, CD62L, and CD49d on U937 were analyzed by FC. Briefly, U937 cells cultured in RPMI (Sigma) +10% FCS were counted and diluted to a concentration of 2 × 10^5 /ml. In a first series of experiments, U937 were cultured in the presence or absence of different dilutions of AD-MSCs-CM and HNDFs-CM for 24 hours. Afterwards, the cells were washed and pulsed with TNFα 25 ng/ml for a further 12 hours. At the end of incubations, U937 were treated, for 20'room temperature in dark room, with the different adhesion molecules antibodies. After washing cells to remove not-conjugated antibodies, adhesion molecules expression was analyzed by FC. Using a similar procedure, we also evaluated the adhesion molecules expression on AD-MSCs and on HNDFs pulsed or not for 12 hours with TNFα 25 ng/ml. ELISA-kits were used to quantify the production of RANTES and MCP-1 (R&D Systems, UK, Europe) by U937 under basal culture conditions, in the presence of inflammatory stimuli (LPS 1 μg/ml and TNFα 25 ng/ml) and in the presence of AD-MSCs-CM and HNDFs-CM. Finally, we also evaluated the effect of AD-MSCs-CM and HNDFs-CM on RANTES and MCP-1 release by U937, after priming with TNFα. Briefly, AD-MSCs and HNDFs were exposed for 12 hours to TNFα 25 ng/ml. Thereafter, cells were washed and further incubated for 24 hours. At the end of incubation, their CMs were collected and tested on U937 chemokines production. All the data were normalized for 10^6 cells in 24 hours incubation, and the basal level production of the same chemokines present in the AD-MSCs-CM and in HNDFs-CM was subtracted.

Statistical analysis

Results are expressed as mean ± standard deviation (SD). Statistical significance was evaluated by analysis of variance followed by Tukey-Kramer multiple comparison test and by Student's t-test. A p value of less than 0.05 denotes statistical significance.

Results

Culture of AD-MSCs and HNDFs showed a very similar morphological appearance and phenotypic profile

AD-MSCs were isolated from subcutaneous fat specimens obtained from 3 patients during the course of abdominal surgery. AD-MSCs were cultured using EGM medium supplemented with 10% FCS and bFGF. Successful isolation and culture expansion of AD-MSCs were obtained from all three specimens processed. HNDF cell lines were maintained in vitro under the same culture conditions of AD-MSCs. HNDFs and AD-MSCs proliferated well in culture with an average doubling time of 28-36 hrs and 38-46 hrs respectively. Cells were usually plated in T25 culture flasks at a density of 20,000 cells/cm². Soon after culture, AD-MSCs showed typical fibroblast-like morphology and did not display any particular morphological differences when compared to HNDFs, even upon 10 in vitro passages (Additional file 1: Figure S1).

The phenotypic profile of AD-MSCs and HNDFs was determined by FC analysis and was performed upon 5 in vitro passages. At first, we analyzed the presence of stem cell markers such as CD34, Stro-1, CD146, CD117, CD133 and ALDH. As reported in Table 1, neither AD-MSCs nor HNDFs expressed the stem cell markers investigated, only ALDH was significantly expressed in approximately 40% of the cells, but again, there was no substantial difference between AD-MSCs and HNDFs (Additional file 2: Figure S2).

Table 1
### Phenotypic characterization of human AD-MSCs and HNDFs

|                      | AD-MSCs % of positive cells (±SD) | HNDFs % of positive cells (± SD) |
|----------------------|----------------------------------|---------------------------------|
| **Stem cell markers**|                                  |                                 |
| Stro-1               | 3.7 ± 3.2                        | 5.5 ± 0.4                       |
| CD146                | 1.5 ± 1.0                        | 1.2 ± 1.2                       |
| CD133                | 0.4 ± 0.3                        | absent                          |
| CD34                 | absent                           | absent                          |
| CD117                | 0.1 ± 0.1                        | absent                          |
| ALDH                 | 42 ± 8.3                         | 41.0 ± 5.4                      |
| **Mesenchymal markers**|                                  |                                 |
| CD105                | 98.4 ± 1.0                       | 95.6 ± 2.2                      |
| CD90                 | 97.6 ± 2.5                       | 94.1 ± 3.2                      |
| CD44                 | 92.5 ±3.6                        | 97.1 ± 1.1                      |
| CD29                 | 95.5 ± 2.0                       | 91.1 ± 5.4                      |
| **AM markers**       |                                  |                                 |
| CD166                | 66.1 ± 26.4                      | 80.4 ± 5.8                      |
| CD106                | 25.2 ± 15.1                      | 35.6 ± 7.8                      |
| CD54                 | 19.6 ± 9.4                       | 25.7 ± 15.5                     |
| CD56                 | 17.8 ± 12.2                      | 39.6 ± 5.6*                     |
| CD49d                | 10.8 ± 3.4                       | 58.9 ± 22.4**                   |
| **Endothelial markers**|                                  |                                 |
| CD31                 | absent                           | absent                          |
| vWf                  | absent                           | absent                          |
| **Immunological markers**|                                 |                                 |
| CD40                 | 17.7 ± 5.9                       | 84.1 ± 3.6**                    |
| CD80                 | 4.6 ± 1.1                        | 2.1 ± 0.9                       |
| CD86                 | 2.6 ± 1.1                        | 0.8 ± 0.7                       |
| CD45                 | absent                           | absent                          |
| HLA-II               | 0.5 ± 0.5                        | 1.1 ± 1.2                       |
| HLA-I                | 93.3 ± 3.3                       | 94.0 ± 2.8                      |

Table shows the phenotypic characterization of AD-MSCs and HNDFs in culture. FACS analysis was performed when all cultures were at 5 in vitro passages. Data represent the % of positive cells for each marker analyzed on AD-MSCs and on HNDF and are means ± SD. Variability of each marker tested among the different cell preparations were ≤ 10%. Note that some markers such as CD56, CD49d and CD40 are more highly expressed in HNDFs when compared to AD-MSCs. *p < 0.05 and **p < 0.01 compared to AD-MSCs.

AD-MSCs and HNDFs display similar differentiation capacity

A typical feature of MSCs is their multipotential differentiation capacity [2, 3]. Previous reports indicate that MSCs of different tissue origin have the capacity to differentiate into different cell lineages, while the multipotential differentiation capacity of fibroblasts is more controversial [14]. Therefore, we compared the capacity of AD-MSCs and HNDFs to differentiate into different cell lineages. Under the same differentiation culture conditions, AD-MSCs and HNDFs were induced to differentiate into osteogenic, adipogenic and cardiomyocyte-like cells. As shown in Figure 1, AD-MSCs and HNDFs differentiate well into osteoblast-like and into adipocyte-like cells assessed by the positivity to AP and Oil Red O staining respectively (Figure 1A). To further confirm adipogenic differentiation, AD-
MSCs and HNDFs were also analyzed for Adiponectin expression, a hormone specifically produced by mature adipocyte [22]. Upon adipogenic differentiation, we found a similar significant increment of Adiponectin expression in both AD-MSCs and HNDFs (Additional file 4: Figure S4). They both differentiated into cardiomyocyte-like cells, although a more intense staining of MyoA, TNP-C and Desmin on AD-MSCs was observed (Figure 1B). Other myocardial markers, such as Cx43 and atrial natriuretic factor, were not detected on either HNDFs or AD-MSCs (data not shown).

Figure 1

AD-MSCs and HNDFs display similar capacity to differentiate into adipogenic, osteogenic and cardiomyogenic cell lineages. The Figure shows the capacity of AD-MSCs and HNDFs to differentiate toward the adipogenic, osteogenic and cardiomyogenic cell lineages in the presence of lineage-specific induction factors. In (A) is shown the positive staining of AD-MSCs and HNDFs for Oil Red O and AP, indicating differentiation into adipogenic and osteogenic cell lineages respectively (magnification 20x). In (B) note the positive immunofluorescence staining of AD-MSCs and HNDFs for Desmin, MyoA and TNP-C cardiomyogenic markers (magnification 10x).

AD-MSCs, but not HNDFs, possess strong angiogenic potential in vitro

To define the angiogenic activity of AD-MSCs and HNDFs, we first analyzed the production of angiogenic growth factors and cytokines in their CM. AD-MSCs and HNDFs were cultured for 72 hours, CM was then analyzed by ELISA for the presence of VEGFa, HGF, TGFβ1, Ang-1, Ang-2 and PDGF. AD-MSCs demonstrated a great capacity to produce a broad spectrum of angiogenic factors (Figure 2). In 72 hours of culture, $10^6$ cells produced an extremely high level of the angiogenic factors HGF and VEGFa. AD-MSCs produced also significant amounts of TGFβ1, Ang-1 and Ang-2 and, to a minor extent, PDGF. Interestingly, HNDFs had a significantly lower production of all the angiogenic factors analyzed. Compared to AD-MSCs, VEGF, HGF and Ang-1 production in HNDFs was significantly lower. We also analyzed the production of angiogenic cytokines, such as IL6 and IL8, which were produced in good quantities by both kinds of mesenchymal cells (Additional file 5: Figure S5).

Figure 2
AD-MSCs, but not HNDFs, produce high levels of angiogenic factors. ELISA-tests were performed to detect VEGFa, TGF-β1, HGF, PDGF, Ang-1 and Ang-2 angiogenic factors released by AD-MSCs and HNDFs in the CM. Note that AD-MSCs, compared to HNDFs, release very high quantities of VEGFa, HGF and Ang-1. Data are the absolute values expressed as mean ± SD of the secreted factor per 10⁶ cells after 72 hrs of incubation. The background values of angiogenic factors contained in EGM control medium (supplemented with 10% FCS and 50 ng/ml bFGF) were subtracted. Tests were run in triplicate and repeated twice. ** p < 0.01 versus HNDFs release.

The angiogenic capacity of AD-MSCs and HNDFs was also evaluated on the proliferation of HUVECs and HMECs. As shown in Figure 3, the addition of AD-MSCs-CM, at all different dilutions tested, enhanced growth of both HUVECs (Figure 3A) and HMECs (Figure 3B). In contrast, the addition of different dilutions of HNDFs-CM did not enhance the proliferation of either HUVECs (Figure 3A) or HMECs (Figure 3B). The capacity AD-MSCs and HNDFs to stimulate angiogenesis was also tested in vitro by evaluating the formation of capillary-like structures on matrigel. AD-MSCs-CM and HNDFs-CM were added to HMECs cultured on matrigel, a matrix that induces capillary-like structure formation that usually regresses within 3–4 days of culture [18]. As shown in Figure 3C and 3D, within 2 days, the presence of AD-MSCs-CM in the control medium substantially triplicated (AD-MSCs-CM 25 ± 17 versus HNDFs-CM 8 ± 6) the number of HMECs tube formations. Moreover, compared to HNDFs-CM, AD-MSCs-CM produced a significant delay of capillary-like structures regression (Figure 3C and 3D). The effect of AD-MSCs-CM on HUVECs was similar (data not shown).

**Figure 3**
AD-MSC-CM possess a higher capacity to stimulate HUVECs and HMECs proliferation and tube formations compare to HNDFs-CM. The effect of AD-MSCs-CM and HNDFs-CM on proliferation of HUVECs (A) and HMECs (B) was tested by adding different dilutions to EGM control medium. As a positive growth control, we used VEGFa 10 ng/ml. AD-MSCs-CM addition had a great capacity to stimulate the proliferation of HMECs (B) and to a minor extent HUVECs (A), while HNDFs-CM addition did not affect ECs proliferation at any dilution tested. In (C) and in (D), we are shown the capacity of AD-MSCs-CM and HNDFs-CM to induce HMECs tube formation respectively. AD-MSCs-CM and HNDFs-CM were added at a ratio 1:1 with EGM control medium (Magnification 10×). Note that AD-MSCs-CM not only increased HMECs tube formation on day 2, but also delayed their regression on day 5. The columns in (A) and (B) are mean ± SD of three independent experiments run in triplicate. *p < 0.05 and **p < 0.01 versus CTRL.

AD-MSCs, but not HNDFs, possess strong anti-inflammatory activity in vitro

It has been shown that MSCs display anti-inflammatory capacity [15, 23, 24]. We thus investigated whether AD-MSCs and HNDFs may produce molecules with anti-inflammatory activity by testing their CM on U937, a human monocyte cell line, under basal culture conditions or in the presence of TNFα inflammatory stimuli. As shown in Figure 4, the expression of the adhesion molecules CD54, CD44, CD62L, CD49d on U937 was not significantly affected by the addition of both AD-MSCs-CM and HNDFs-CM to the basal control medium. After stimulation of U937 with TNFα (25 ng/ml), expression of CD54 (Figure 4A), CD44 (Figure 4B) and CD62L (Figure 4C) was increased and the addition of AD-MSCs-CM (at 1:1 dilution) was able to antagonize the increment (Figure 4A, B and 4C). In contrast, the addition of HNDFs-CM did not affect adhesion molecules induced by TNFα; only CD54 expression was slightly reduced (Figure 4A). Neither AD-MSCs-CM nor HNDFs-CM had any affect on CD49d expression (Figure 4D).
AD-MSCs, but not HNDFs, reduced expression of AMs on U937. AD-MSCs-CM and HNDFs-CM were tested on the adhesion molecules expression of the U937 monocyte cell line stimulated or not with TNFα (25 ng/ml × 12 hrs). Mean Fluorescent Intensity (MFI) of each marker expression was evaluated by FACS and values are the mean ± SD of independent experiments performed with 3 different preparations of AD-MSCs-CM and HNDFs-CM. In (A) the expression of CD54/ICAM-1, (B) the expression of CD44, (C) the expression of CD42L/L-selectin and in (D) the expression of CD49d/VLA-4. Note that, both AD-MSCs-CM and HNDFs-CM did not affect basal adhesion molecules expression on U937. However, AD-MSCs-CM, but not HNDFs-CM (at 1:1), inhibited CD54/ICAM-1, CD44 and CD42L/L-selectin up-modulation produced by TNFα stimuli. CD49d expression was not affected by either AD-MSCs-CM or HNDFs-CM. * p < 0.05 and **p < 0.01 versus CTRL.

We also investigated the effect of AD-MSCs-CM and HNDFs-CM on CD11a and CD11b expression, adhesion molecules that are involved in inflammatory cells migration [25]. Only AD-MSCs-CM, but not HNDFs-CM, induced a slight decrement of CD11a and CD11b expression on U937 (Additional file 6: Figure S6). We next investigated the capacity of AD-MSCs-CM and HNDFs-CM to affect the release of RANTES and MCP-1 inflammatory chemokines by U937, under basal culture conditions or in the presence of TNFα and LPS stimuli. AD-MSCs and HNDFs, per se, released very little amounts of both RANTES and MCP-1 (< 20 pg/ml for each chemokine) (data not shown). However, as shown in Figure 5, the addition of AD-MSCs-CM to U937 culture greatly inhibited RANTES (Figure 5A) and MCP-1 (Figure 5B) release in a dose dependent manner either in the presence or absence of LPS (1 μg/ml) inflammatory stimulation. By contrast, however, the addition of HNDFs-CM at every dilution tested did not (Figure 5A and 5B). The capacity of AD-MSCs-CM to block RANTES and MCP-1 chemokines release was even more potent if U937 was stimulated with TNFα for 12 hours (Figure 5C and 5D).

Finally, we asked whether exposing AD-MSCs and HNDFs to the inflammatory cytokine TNFα may induce changes in their activity on U937 chemokines release. To this end, AD-MSCs and HNDFs were primed for 12 hours with TNFα (25 ng/ml), thereafter the medium was replaced with fresh medium, and 24 hours later CM was recovered and tested on U937 chemokines production. As shown in Figure 6, TNFα primed-AD-MSCs-CM (P-AD-MSCs-CM) added to U937 enhanced inhibition of RANTES and MCP-1 release by U937, either in the presence or absence of TNFα stimuli. Thus, priming with TNFα improved anti-inflammatory activity of AD-MSCs on U937 chemokines release. Interestingly, the addition of TNFα primed-HNDFs-CM (P-HNDFs-CM) produced, by contrast, a significant increment of chemokines release by U937 (Figure 6), indicating that HNDFs, under stimulation with TNFα, behave in an opposite manner.
Addition of AD-MSCs-CM, but not HNDFs-CM, to U937 blocked production of RANTES and MCP-1 by U937. ELISA kits were used to quantify the production of RANTES and MCP-1 by U937 under basal culture conditions, in the presence of inflammatory stimuli LPS (1 μg/ml) (A and B) and TNFα (25 ng/ml) (C and D) and in the presence of AD-MSCs-CM and HNDFs-CM. In (A) RANTES and in (B) MCP-1 production are blocked in a dose dependent manner by the addition of AD-MSCs-CM but not by HNDFs-CM under basal or in the presence of LPS. Similarly, in (C) RANTES and in (D) MCP-1 release is inhibited by the addition of AD-MSCs-CM to U937 stimulated or not with TNFα for 12 hrs. The columns in the figure are mean ± SD of three independent experiments run in triplicate. *p < 0.05 and **p < 0.01 versus CTRL.

Figure 6
Priming of AD-MSCs and HNDFs with TNFα induce an opposite effect on RANTES and MCP-1 release by U937. AD-MSCs and HNDFs were primed for 12 hrs with TNFα 25 ng/ml. Thereafter cells were washed and further incubated for 24 hrs. At the end of incubation, CMs were collected from primed AD-MSCs (P-AD-MSCs-CM) and primed HNDFs (P-HNDFs-CM) and tested on U937 chemokines production. Note that, while the addition of P-AD-MSCs-CM to U937 completely blocked RANTES and MCP-1 release, in an opposite manner, P-HNDFs-CM improved their release. The columns in the figure are mean ± SD of two independent experiments run in triplicate. ° p < 0.05 and °° p < 0.01 versus HNDF-CM, *p < 0.05 and **p < 0.01 versus AD-MSCs-CM, + p < 0.05 and ++ p < 0.01 versus CTRL.

Discussion

Among the different stem cell phenotypes, adult MSCs represent an extremely valid cell option to apply to regenerative therapies. Besides their capacity to differentiate into many different cell lineages, including neural cells [26], MSCs display immunosuppressive [27], anti-inflammatory [15, 23], anti-apoptotic [28] and angiogenic activity [15, 28]-all distinguishing features of cells with potential regenerative properties [29]. In addition, MSCs can be isolated from many different adult human tissues [2–7]; in particular, BM and adipose tissue are sufficiently rich in MSCs content. For this reason, MSCs derived from BM and adipose tissue have been investigated more deeply and have been found to show similarities in terms of phenotypic profile, differentiation potential and in vivo regenerative capacity [7].

Procedures for their extraction and culture expansion have been fully described [2, 3]. However, one of the major unsolved problems is the purity of MSCs preparation to use for therapeutic purposes. In fact, because of a lack of specific MSC markers, the presence of contaminating mature stromal cells, such as fibroblasts, cannot be distinguished and quantified, particularly in a fresh preparation or even in an expanded culture of AD-MSCs. Data from Lennon et al indicate that human BM-MSCs intentionally contaminated by dermal fibroblasts continue to elicit a positive osteochondrogenesis both in vitro and in vivo [30]. However, since there are very few comparative studies between AD-MSCs and fibroblasts and because the grade of purity of AD-MSC preparations may directly affect their in vivo efficacy [31, 32], in the present study, we asked whether AD-MSCs are unique or whether they may share essential characteristics with fibroblasts. To this end, we compared the phenotypic and functional features of AD-MSCs and two dermal fibroblast cell lines. AD-MSCs were prepared from three different human donors following a standard procedure [15]. In contrast, we decided to use two commercial established fibroblast cell lines, to reduce the presence of cross-contaminating MSCs-like cells which could be present in fresh culture of dermal fibroblasts [10]. Moreover, commercial cell lines, are usually well characterized and composed of a more homogenous cell population if compared to fresh cell preparations. In fact, FC analysis of the two HNDF cell lines used confirmed the high level of stromal cell purity; cells were almost 100% positive for each mesenchymal marker tested (Table 1). In this regard, the analysis of the phenotypic profile confirms previous publications that indicate the absence of distinguishing markers in AD-MSCs and HNDFs [10, 14]; they both expressed typical MSCs markers, were
negative for endothelial and hematopoietic markers and even similarly negative for many stem cell markers, in particular Stro-1 and CD146, which are, by contrast, described on BM-MSCs [11, 13]. Only ALDH activity, a stemness functional marker used for identification of stem cells and progenitors [16], was similarly present on both AD-MSCs and HNDFs. In this study, we also investigated the presence of immunogenic cell surface molecules on AD-MSCs and HNDFs. We found that CD54, CD80 and CD86 were similarly expressed, by contrast, CD40, a co-stimulatory protein found on APCs [20], was more highly expressed only on HNDFs. These data suggest that mature fibroblasts could have a higher immunogenic profile than AD-MSCs. In fact, the presence of very low levels of CD40 combined with the absence of CD14 and HLA-DR may not be sufficient to endow AD-MSC with APC function. In this study, we did not investigate the immunosuppressive activity of AD-MSCs and HNDFs, because publications have already well described the immunosuppressive activity of both fibroblasts and MSCs [27, 33].

We could not find any differences between AD-MSCs and HNDFs regarding morphological appearance in culture, growth rate and, more interestingly, in multipotential differentiation capacity. Hence our results are in contrast with Wagner et al [14] but support the finding of Lorenz et al who propose dermal fibroblasts for application in the therapy of wound healing because of their multilineage differentiation potential [10].

Besides this aspect, in our opinion this study has disclosed important new insights into functional differences between AD-MSCs and HNDFs. More specifically, it is known that HNDFs play an important role in angiogenesis, providing the extracellular matrix molecules necessary to support capillary morphogenesis [34] and a balance of pro-angiogenic and anti-angiogenic factors to determine the final vascular density [35, 36]. We did not investigate the production of extracellular matrix proteins produced by AD-MSCs and HNDFs in culture, but instead, we studied both the content of angiogenic growth factors, such as VEGFα, HGF, TGFβ1, Ang-1 and Ang-2 and PDGF released in the CM and, concomitantly, their activity on ECs proliferation and tube-like formations. We demonstrated, for the first time, that AD-MSCs were extremely more angiogenic then HNDFs. Indeed, if compared to HNDFs-CM, the level, in particular of VEGFα, HGF and Ang-1, was significantly higher in the AD-MSCs-CM as was its capacity to stimulate ECs proliferation. This data is consistent with our [15] and other previous reports [29] indicating the strong angiogenic potential of AD-MSCs and their potential use for the therapy of ischemic diseases [15, 29]. Vice-versa, HNDFs appear less angiogenic. Although it is still under debate, if fibroblasts can be considered more mature cells than MSCs, our data may indicate that the angiogenic potential of MSCs could be inversely related with their grade of maturation, explaining, at least in part, the reason why dermal fibroblasts are less efficient than MSCs in promoting wound healing [37]. In addition AD-MSCs, but not HNDFs, were able to improve and stabilize HMECs tube-like formation, probably through their capacity to secrete significant quantities of Ang-1, an angiogenic factor involved in vascular morphogenesis [38]. This result expands on previous observations proposing that MSCs are different from fibroblasts and more similar to pericytes, [39] also because MSCs and pericytes are located in the wall of vasculature [6, 40].

This study confirms the strong anti-inflammatory potential of AD-MSCs [15, 23] and concomitantly highlights, for the first time, that HNDFs lack this property. In our opinion, this appears to be the most distinguishing feature between AD-MSCs and HNDFs. AD-MSCs were able to reduce adhesion molecules expression and inhibit the U937 release of the inflammatory chemokines RANTES and MCP-1, under different inflammatory stimuli. HNDFs did not affect any of the inflammatory activities of U937 monocytes. More interestingly, our results disclose a little-studied characteristic of AD-MSCs and HNDFs. Indeed, we observed that, under inflammatory stimuli, AD-MSCs and HNDFs behave in an opposite manner on U937 chemokines release. Upon priming with TNFα, AD-MSCs increased their capacity to block the release of RANTES and MCP-1, while HNDFs, by contrast, acquired pro-inflammatory activity, enhancing chemokines release by U937. To our knowledge, this is a new finding, that could be used not only to clearly distinguish between AD-MSCs and fibroblasts preparations, but also to improve MSCs regenerative properties when applied to cell therapy of ischemic diseases [41]. In addition, enhancing anti-inflammatory activity of MSCs may provide a better strategy to affect diseases where inflammation plays an important role in supporting progression.

Conclusions

This study shows evidence that AD-MSCs and HNDFs share a number of similar phenotypic functional features, including the capacity to differentiate into different cell lineages. We demonstrate that, to distinguish AD-MSCs and HNDFs cultures, it is necessary to evaluate their angiogenic and, overall, their anti-inflammatory potential. AD-MSCs are significantly more angiogenic and anti-inflammatory than HNDFs. In addition, under stimulation with TNFα, AD-MSCs and HNDFs behave in an opposite manner: AD-MSCs improve anti-inflammatory activity, while HNDFs enhance inflammation. All together these data suggest that, before application in cell-based therapy, preparations of MSCs require testing for their angiogenic and anti-inflammatory capacity. Priming them with inflammatory cytokines may be useful for improving their therapeutic efficacy.

Additional file 1: Figure S1 Morphological appearance of AD-MSCs and HNDFs in culture. The Figure shows the culture of AD-MSCs and HNDFs at early (P3) and at late (P10) in vitro passages. Note that AD-MSCs as well as HNDFs have a similar fibralastic-like morphology (magnification 10x) (PDF 62 KB)
Additional file 2: Figure S2 AD-MSCs and HNDFs show a similar ALDH expression. Aldefluor test was used to identify stem and progenitor cells with low side scatter that expressed high levels of ALDH. The Figure shows FC analysis of ALDH expression on both AD-MSCs and HNDFs. Note that both kinds of cell culture contained a similar percentage of ALDH positive cells. (PDF 60 KB)

Additional file 3: Figure S3 Marker's expression of AD-MSCs and HNDFs. Note the high expression of mesenchymal markers CD90, CD44, CD105, CD73 and CD166 on both AD-MSCs and HNDF, whereas HNDFs expressed higher levels of CD40 and CD49d. (PDF 92 KB)

Additional file 4: Figure S4 AD-MSCs and HNDFs produce high level of Adiponectin after adipogenic differentiation. Adiponectin expression was used to confirm adipogenic differentiation of AD-MSCs and HNDFs. The figure shows the FC of Adiponectin expression before and after adipogenic differentiation of AD-MSCs and HNDFs. Note that both kinds of cell culture expressed high level of Adiponectin after differentiation. (PDF 60 KB)

Additional file 5: Figure S5 AD-MSCs, and HNDFs, produce high levels of IL6 and IL8. ELISA-tests were performed to detect IL6 and IL8 cytokines released by AD-MSCs and HNDFs in the CM. Note that both AD-MSCs, and HNDFs, release a high quantity of IL6 and IL8. Data are expressed as mean ± SD of the secreted factor per 10^6 cells after 72 hrs of incubation. Tests were run in triplicate and repeated twice. The background values contained in EGM control medium were subtracted (PDF 14 KB)

Additional file 6: Figure S6 AD-MSCs-CM, but not HNDFs-CM, reduced expression of CD11a and CD11b on U937 monocytes. Note that the addition of AD-MSCs-CM (1:1), but not HNDFs-CM, to U937 culture medium slightly reduced MFI of CD11a CD11b, particularly upon stimulation with TNFα. (PDF 30 KB)

**Abbreviations**

- **Adipose-derived MSCs**
- **conditioned medium-derived AD-MSCs**
- **aldehyde dehydrogenase**
- **Angiopoietin-1**
- **Angiopoietin-2**
- **Alkaline phosphatase**
- **antigen presenting cells**
- **bone marrow**
- **bone marrow derived MSCs**
- **conditioned medium**
- **Connexin 43**
- **endothelial cells**
- **FC:** Flow cytometry
- **Hepatocyte growth factor**
- **Human normal dermal fibroblasts**
- **conditioned medium-derived HNDF**
- **human microvascular endothelial cells**
- **human umbilical vein endothelial cells**
- **mesenchymal stem cells**
- **myocardial actin**
• lipopolisaccaride
• priming-derived AD-MSCs-CM
• platelet derived growth factor
• priming-derived HNDFs-CM
• smooth muscle cells
• transforming growth factor \( \beta 1 \)
• tumor necrosis factor \( \alpha \)
• cardiac troponin
• vascular endothelial growth factor
• von Willebrand factor

Declarations

Acknowledgements

We thank Dr Andrea Smith for checking the English of the manuscript.

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.
Authors’ original file for figure 1
Authors’ original file for figure 2
Authors’ original file for figure 3
Authors’ original file for figure 4
Authors’ original file for figure 5
Authors’ original file for figure 6

Antonella Blasi, Carmela Martino contributed equally to this work.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All authors have read and approved the final manuscript. AB, CM designed experiments, differentiation experiments, performed in vitro experiments on U937, performed FACS analysis and ELISA assay. LB, MS Isolation and culture AD-MSCs, immunofluorescent characterization. SEN, LC, SC, and GI Performed experiments on ECs and Matrigel assay, isolation and culture of HUVECs and HMECs, AS, EAP supervised the manuscript, GA conceived, directed the study, and wrote the manuscript.

References

1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147.
   View Article   Google Scholar

2. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:D42-D49.
   View Article   Google Scholar
3. Zuk PA Zhu M Ashjian P De Ugarte DA Huang JI Mizuno H Alfonso ZC Fraser JK Benhaim P Hedrick MH Human adipose tissue is a source of multipotent stem cells Mol Biol Cell 2002 13 4279 4295138633 10.1091/mbc.E02-02-0105

4. Hu Y, Liao L, Wang Q, Ma L, Ma G, Jiang X, Zhao RC. Isolation and identification of mesenchymal stem cells from human fetal pancreas. J Lab Clin Med. 2003;141:342-349. View Article Google Scholar

5. Nakatsuka R, Nozaki T, Uemura Y, Matsuoka Y, Sasaki Y, Shinohara M, Ohura K, Sonoda Y. 5-Aza-2'-deoxycytidine treatment induces skeletal myogenic differentiation of mouse dental pulp stem cells. Arch Oral Biol. 2010;55:350-357. View Article Google Scholar

6. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, Teng PN, Tras J, Schugur R, Deasy BM, Badylak S, Huard J, Péault B. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3:301-313. View Article Google Scholar

7. Yoshimura H, Muneta T, Nimura A, Yokoyama A, Koga H, Sekiya I. Comparison of rat mesenchymal stem cells derived from bone marrow, synovium, periosteum, adipose tissue, and muscle. Cell Tissue Res. 2007;327:449-462. View Article Google Scholar

8. Boquest AC, Shahdadfar A, Brinchmann JE, Collas P. Isolation of stromal stem cells from human adipose tissue. Methods Mol Biol. 2006;325:35-46. View Article Google Scholar

9. Linge C, Green MR, Brooks RF. A method for removal of fibroblasts from human tissue culture system. Exp Cell Res. 1989;185:519-528. View Article Google Scholar

10. Lorenz K, Sicker M, Schmelzer E, Rupf T, Salvetter J, Schulz-Siegmund M, Bader A. Multilineage differentiation potential of human dermal skin-derived fibroblasts. Exp Dermatol. 2008;17:925-932. View Article Google Scholar

11. Gronthos S, Graves SE, Ohta S, Simmons PJ. The STRO-1+ fraction of adult human bone marrow contains the osteogenic precursors. Blood. 1994;84:4164-4173. View Article Google Scholar

12. Bruno S, Bussolati B, Grange C, Collino F, di Cantogno LV, Herrera MB, Biancone L, Tetta C, Segoloni G, Camussi G. Isolation and characterization of resident mesenchymal stem cells in human glomeruli. Stem Cells Dev. 2009;18:867-880. View Article Google Scholar

13. Sorrentino A, Ferracini M, Castelli G, Biffoni M, Tomaselli G, Baiocchi M, Fatica A, Negrini M, Peschle C, Valtieri M. Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp Hematol. 2008;36:1035-1046. View Article Google Scholar

14. Wagner W, Wein F, Seckinger A. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol. 2005;33:1402-1416. View Article Google Scholar

15. De Siena R, Balducci L, Blasi A, Montanaro MG, Saldarelli M, Saponaro V, Martino C, Logrieco G, Soleti A, Fiobellot S, Madeddu P, Rossi G, Ribatti D, Crovace A, Cristini S, Invernici G, Parati EA, Alessandri G. Omentum-derived stromal cells improve myocardial regeneration in pig post-infarcted heart through a potent paracrine mechanism. Exp Cell Res. 2010;316:1804-1815. View Article Google Scholar

16. Moreb JS. Aldehyde dehydrogenase as a marker for stem cells. Curr Stem Cell Res Ther. 2008;3:237-246. View Article Google Scholar
17. Alessandri G, Chirivi RG, Fiorentini S, Dossi R, Bonardelli S, Giulini SM, Zanetta G, Landoni F, Grazioti PP, Turano A, Caruso A, Zardi L, Giavazzi R, Bani MR. Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells. Clin Exp Metastasis. 1999;17:655-662. View Article Google Scholar

18. Kleinman HK, Martin GR. Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol. 2005;15:378-386. View Article Google Scholar

19. Steingen C, Brenig F, Baumgartner L, Schmidt J, Schmidt A, Bloch W. Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. J Mol Cell Cardiol. 2008;44:1072-1084. View Article Google Scholar

20. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229:152-172. View Article Google Scholar

21. Fries KM, Sempowski GD, Gaspari AA, Blieden T, Looney RJ, Phipps RP. CD40 expression by human fibroblasts. Clin Immunol Immunopathol. 1995;77:42-51. View Article Google Scholar

22. Ukkola O, Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities?. J Mol Med. 2002;80:696-702. View Article Google Scholar

23. Tanaka F, Tominaga K, Ochi M, Tanigawa T, Watanabe T, Fujiwara Y, Ohta K, Oshitani N, Higuchi K, Arakawa T. Exogenous administration of mesenchymal stem cells ameliorates dextran sulfate sodium-induced colitis via anti-inflammatory action in damaged tissue in rats. Life Sci. 2008;83:771-779. View Article Google Scholar

24. Nasef A, Chapel A, Mazurier C, Bouchet S, Lopez M, Mathieu N, SensebÉ L, Zhang Y, Gorin NC, Thierry D, Fouillard L. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr. 2007;13:217-226. View Article Google Scholar

25. Paulsson JM Dadfar E Held C Jacobson SH Lundahl J In vivo transmigrated monocytes from patients with stable coronary artery disease have a reduced expression of CD11b Clin Exp Immunol 2008 153 196 2042492892 10.1111/j.1365-2249.2008.03676.x

26. Jiang J, Lv Z, Gu Y, Li J, Xu L, Xu W, Lu J, Xu J. Adult rat mesenchymal stem cells differentiate into neuronal-like phenotype and express a variety of neuro-regulatory molecules in vitro. Neurosci Res. 2010;66:46-52. View Article Google Scholar

27. Nasef A, Mathieu N, Chapel A, Frick J, Franqois S, Mazurier C, Boutarfa A, Bouchet S, Gorin NC, Thierry D, Fouillard L. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation. 2007;84:231-237. View Article Google Scholar

28. Park KS, Kim YS, Kim JH, Choi B, Kim SH, Tan AH, Lee MS, Lee MK, Kwon CH, Joh JW, Kim SJ, Kim KW. Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation. Transplantation. 2010;89:509-517. View Article Google Scholar

29. Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol. 2009;217:318-324. View Article Google Scholar

30. Lennon DP, Haynesworth SE, Arm DM, Baber MA, Caplan AI. Dilution of human mesenchymal stem cells with dermal fibroblasts and the effects on in vitro and in vivo osteochondrogenesis. Dev Dyn. 2000;219:50-62. View Article Google Scholar
31. Mosna F, Sensebé L, Krampera M. Human Bone-Marrow And Adipose Tissue Mesenchymal Stem Cells: A User's Guide. Stem Cells Dev. 2010;19:1449-1470.

32. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy. 2006;8:315-317.

33. Sarkhosh K, Tredget EE, Karami A, Uludag H, Iwashina T, Kilani RT, Ghahary A. Immune cell proliferation is suppressed by the interferon-gamma-induced indoleamine 2,3-dioxygenase expression of fibroblasts populated in collagen gel (FPCG). J Cell Biochem. 2003;90:206-217.

34. Berthod F, Germain L, Tremblay N, Auger FAJ. Extracellular matrix deposition by fibroblasts is necessary to promote capillary-like tube formation in vitro. Cell Physiol. 2006;207:491-498.

35. Black AF, Berthod F, L'heureux N, Germain L, Auger FA. In vitro reconstruction of a human capillary-like network in a tissue-engineered skin equivalent. FASEB J. 1998;12:1331-1340.

36. Hudon V, Berthod F, Black AF, Damour O, Germain L, Auger FA. A tissue-engineered endothelialized dermis to study the modulation of angiogenic and angiostatic molecules on capillary-like tube formation in vitro. Br J Dermatol. 2003;148:1094-1104.

37. Wu Y, Wang J, Scott PG, Tredget EE. Bone marrow-derived stem cells in wound healing: a review. Wound Repair Regen. 2008;16:582-.

38. Thomas M, Augustin HG. The role of the Angiopoietins in vascular morphogenesis. Angiogenesis. 2009;12:125-37.

39. Caplan AI. All MSCs are pericytes?. Cell Stem Cell. 2008;3:229-230.

40. Covas DT, Panepucci RA, Fontes AM, Silva WA, Orellana MD, Freitas MC, Neder L, Santos AR, Peres LC, Jamur MC, Zago MA. Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol. 2008;36:642-654.

41. Kim YS, Park HJ, Hong MH, kang PM, Morgan JP, Jeong MH, Cho JG, Park JC, Ahn Y. TNF-alfa enhances engraftment of mesenchymal stem cells into infacted myocardium. Front Biosci. 2009;14:2845-2856.